___

• Salford LG, Plum F, Berierley JB. Graded hypoxia-oligemia in rat brain. II. Neuropathological alterations and their implications. Arch Neurol, 1973;29:234.
• Özbay G. Hemodinamik bozukluklar, tromboz ve şok. In: Kumar V, Cotran RS, Robins SL
• (eds). Temel Patoloji. 6
• th, İstanbul: Nobel Kitabevleri, 2000: 60.
• Touzani O, Young AR. Progressive impairment of brain oxidative metabolism reversed by reperfusion following middle cerebral artery occlusion in anaesthetized baboons. Brain Res.1997:767: 17-25.
• Sharp FR, Lu A, Tang Y, Millhorn DE. Multiple molecular penumbras after focal cerebral ischemia. J Cereb Blood Flow Metab. 2000 : 20:1011-1032.
• Fishman RA. Brain edema. N Engl J Med, 1975;293:706.
• Rothman S. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J Neurosci, 1984; 4: 1884.
• Muir KW, Less KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke, 1995; 26: 503. 15
• Siejko BK. Pathophysiology and treatment of focal cerebral ischemia. Part II, Mechanisms of damage and treatment. J Neurosurg, 1992; 77:337.
• Slivka A, Brannan TS, Weinberger J, et al. Increase in extracellular dopamine in the striatum during cerebral ischemia: a study utilizing cerebral microdialysis. J Nerochem, 1988;50:1714.
• Weinberger J, Nieves-Rosa J, Colen G. Nerve terminal damage in cerebral ischemia: protective effect of alpha-methyl-paratyrosine. Stroke, 1985;16:864.
• Weinberger J, Nieves-Rosa J. Monoamine neurotransmitters in the evolution in infarction in ischemic striatum: morphologic correlation. J Neurol Trans, 1988;71:133.
• Eliasson MJ, Sampei K, Mandir AS, et al. Poly (AD ribose) polymerase gene disruption render mice resistance to cerebral ischemia. Nat Med, 1997; 3:1089.
• Siejko BK. Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiologia. J Neurosurgery,1992;77:169.
• Brown AW, Brierly JB. The earliest alterations in ratneurones and astrocytes and after anoxia-ischemia. Acta Neuropathol (Berl), 1973;23:9.
• Park CK, Nehls DG, Graham DI, et al. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann. Neurol, 1988;24:543.
• Linnik MD, Miller JA, Sprinkle-Cavolla J, et al. Apoptotic DNA fragmentation in the rat cerebral cortex induced by permanent middle cerebral artery occlusion. Brain Res Mol, 1995;32:116.
• Weinberger J, Cohen G, Nieves-Rosa J. Nerve terminal damage in cerebral ischemia: greater suosceptibility of catecholamine nerve terminals relative to serotonin nerve terminals. Stroke, 1983;14:986. Utku U, Çelik Y. Strokta Etyoloji, Sınıflandırma ve Risk Faktörleri. Serebrovasküler Hastalıklar, Edt. Balkan S. Güneş Kitapevi, Antalya, 2005. 57-71.
• Kutluk K. İskemik inme. İn: Kutluk K. Klinik yaklaşım ve sınıflama. Nobel Tıp Kitapevi,
• İstanbul, 2004:61-73.
• Bougousslavsky J, Regli F, Besson G, et al. Early clinical diagnosis of stroke subtypes. Cerebrovasculer Disease .1993; 3:39-44.
• Adams Jr HP, Bendixen BH, Capelle J, and TOAST investigators. Classifications of subtype of acute ischemic stroke. Definition for use in multicenter clinical trial. Stroke, 1993;24:35.
• Bakaç G. Kardiyoembolik inme. Edt Balkan S. Serebrovasküler Hastalıklar. Güneş Kitapevi, Antalya, 2005, 117-127.
• Dora B, Balkan S. Laküner infarktlar. Edt Balkan S. Serebrovasküler Hastalıklar. Güneş
• Kitapevi, Antalya, 2005, 103-115.
• Steinke W, Ley SC. Lacunar stroke is the major cause of progressive motor deficits. Stroke. 2002; 33: 1510-1516.
• Staessen JA, Fagard R, Thijs L, et al. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: The systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet, 1997;350:757.
• Curp JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Hypertension in the Elderly Program Cooperative Research Group. JAMA, 1996;276:1886.
• Kagan A, Poper JS, Rhoads GG. Factors related to stroke incidence in Hawaii, Japanese man: The Honolulu Heart Study. Stroke, 1980;11:14.
• UK prospective diabetes study group: Tight blood pressure control risk of macrovascular and microvascular complications in Type-II diabetes: UKPDS, 38. BMJ, 1998;317:703.
• Benfante R Yano K, Hwang LJ, et al. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian, Japanese man: Implications of shared risk. Stroke, 1994;25:814. Bakar M, Erhan O. Tıkayıcı Tip Serebrovasküler Hastalıklar. Balkan S edt. Serebrovasküler Hastalıklar; Güneş Kitabevi, Antalya, 2005:83-101.
• The National Instutite of Nourological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acut ischemic stroke. N Engl J Med 1995;333:15811587.
• Taesdale G, Jennet B: Assessment of coma and impaired comsciosness. A practical scale. Lancet 1974;2:81-84.
• Kannel WB, Gordon T, Wolf PA, et all. Hemoglobin and the risk of cerebral infarction: The Franingham study. Stroke, 1972;3:409.
• Silverstein A. Thrombotic thrombocytopenic purpura. The initial neurological manifestations. Arch. Neurol, 1968;18:358.
• The APASS Group: Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology, 1993;43:2069.
• D’Angelo A, Viggano-D’angelo S, Esmon CT, et al. Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation. J. Clin İnvest, 1988;81:1145.
• Kohler J, Kasper J, Witt L, et al. Ischemic stroke due top protein C deficiency. Stroke, 1990;21:1077.
• Hart FG, Miller VT. Cerebral infarction in young adults. A Practical approach. Stroke, 1983;14:110.
• Woo J, Lam CW, Kay R, et al. The influence of hyperglycemia and diabetes mellitus on in mediate and 3-month morbidity and mortality after acute stroke. Arch Neurol, 1990;47:1174.
• Wolf PA, Dawber TR, Thomas HE, et al. Epidemiologic assessment of chronic atrial fibrilation and risk of stroke. The Framingham Study. Neurology, 1978;28:973.
• Weinberger J, Rothlauf E, Materese E, et al. Noninvasive evaluation of the extracranial carotid arteries in patients with cerebrovascular events and atrial fibrilations. Arch Intern Med, 1998;148:1785.
• Dimanth J, Grop D. Electrocardiographic changes and myocardial damage in patients with acute cerbrovascular accidents. Stroke, 1977;8:448.
• Hatano S: Variability of the diagnosis of stroke by clinical judgment and by a scoring method. Bull World Health Org. 1976;54:533.
• Bamford J. Clinical examination in diagnosis and subclassification of stroke. Lancet, 1992; 339:400.
• Önal MZ, Fisher M, Bogousslavsky J. Current Review Of .Cerebrovascular Disease Fourth Edition, edt. Fisher M, Bogousslavsky J, Current Medicine Inc, Philadelphia, 2001, Clinical Evaluation Of Stroke, , 101.
• International Stroke Trial Collaborative Group. The International Stroke Trial (IST): A randomized trial of aspirin, subcutaneous heparin, both or neither among 19.435 patients with acute ischemic stroke. Lancet, 1997;349:1569.
• CAST (Chinese Acute Stroke Trial) Collaboratice Group. CAST: Randomized placebo control trial of early aspirin use in 200.000 patients with acute ischemic stroke. Lancet, 1997;349:668.
• Multicenter Acute Stroke Trial-Italy (MAST-1) Group. Randomized control trial of streptokinase, aspirin, and combination of both in treatment of ischemic stroke. Lancet, 1995;346:1509.
• Adams HP, Adams RJ, Brott T, et al. Guidelines for the early management of patients with ischemic stroke. A scientific statement from the stroke council of the American stroke association. Stroke. 2003;34:1056.
• Cerebral Embolism Study group. Immediate anticoagulation of embolic stroke: A randomized trial. Stroke, 1983;14:668
• Cerebral Embolism TASK Force. Cardiogenic brain embolism. Arch Neurol, 1986;43:7
• Kay R, Wong KS, Yu YL, et al. Low molecular weight heparin for the treatment of acute ischemic stroke. N Eng J Med, 1995;333:1588.
• The Publications Committee for the trial of ORG 10.712 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10.172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial. JAMA, 1998;279:1265.
• Kutluk K. İskemik inme. İn: Kutluk K. Akut Dönemde Antikoagülan Tedavi. Nobel Tıp
• Kitapevi, İstanbul, 2004:165-171.
• Kutluk K. İskemik inme. İn: Kutluk K. Trombolitik Tedavi. Nobel Tıp Kitapevi, İstanbul, 2004:173-190.
• Kutluk K. İskemik inme. İn: Kutluk K. Nöroprotektif Tedavi. Nobel Tıp Kitapevi, İstanbul, 2004: 201-211.
• Işıkay CT, Mutluer N. Strok Komplikasyonları. Edt Balkan S. Serebrovasküler Hastalıklar.
• Güneş Kitapevi, Antalya, 2005, 345-361.
• Dinçel A.S, Sepici V. İnflamasyonun labaratuvar değerlendirilmesi. Çev. Edt. Arasıl T. Kelley
• Romatoloji. 7. baskı. Güneş Kitabevi, Ankara, 2006, 720-725.
• Camcı C. Granülositler ve monositlerin hastalıkları. Çev. Edt Sağlıker Y. Harrıson İç
• Hastalıkları Prensipleri. Nobel tıp kitabevleri. 15. baskı, Adana, 2004,366-374.
• Canataroğlu A, Güvenç B. İmmün sistem hastalıkları. Çev. Edt Sağlıker Y. Harrıson İç
• Hastalıkları Prensipleri. Nobel tıp kitabevleri. 15. baskı, Adana, 2004,1805-1830.
• Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinical subtypes of cerebral infarction. Lancet 1991; 337:1521-1526 Demir S. Proteinler. Çev. Edt. Aslan T. Tietz Klinik Kimyada Temel İlkeler. 5. baskı. Palme Yayıncılık, Ankara, 2005, 325-351. Öztürk Ş. İnmede biyolojik ve elektrofizyolojik tanı özellikleri. Edt Balkan S. Serebrovasküler Hastalıklar. Güneş Kitapevi, Antalya, 2005, 263-288. Borman P. Fibroblast fonksiyonu ve fibrozis. Çev. Edt. Arasıl T. Kelley Romatoloji. 7. baskı. Güneş Kitabevi, Ankara, 2006, 189-202.
• Hakgüder A. Sitokinler. Çev. Edt. Arasıl T. Kelley Romatoloji. 7. baskı. Güneş Kitabevi,
• Ankara, 2006, 379-406.